Investment report featuring Antares Pharma from BeaconEquity.com

BeaconEquity.com announces an investment report featuring medical instruments company Antares Pharma Inc. (AMEX:AIS). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: http://www.beaconequity.com/i/AIS

Get our alerts BEFORE the rest of the market. Follow us on Twitter: https://twitter.com/BeaconEquity

Antares Pharma Inc. (AIS) is engaged in the research, development, production and licensing of self-injection pharmaceutical device products and technologies as well as topical gel-based products. The Company's products focus upon subcutaneous injection technology platforms, including Vibex disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors.   Its gel-based products include lead drug candidate, Anturol, presently in phase III clinical drug trial for the treatment of overactive bladder syndrome.

In the report, the analyst notes:

"The Company's subcutaneous injection business includes licensing of its reusable needle-free injection device to Teva, Fering and JCR for use with human growth hormones (hGH). Teva expects to capture approximately 10% of the hGH market, which is dominated by growth-stunted children squeamish of present drug therapy delivery systems. The Company's fortunes may become directly tied to Teva's marketing efforts in this area and other lucrative markets in the future.

"The Company has generated net losses of $10,290,752, $12,690,453 and $8,578,939 for the fiscal years 2009, 2008 and 2007, respectively. As of its inception through December 31, 2009, the Company has accumulated $130,882,597 in losses. The Company said in its latest 10-k dated March 24, 2010 that it expects losses to continue through December 31, 2010. Management believes that it has sufficient operating cash for at least 12 months."